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kidney injury after pharmacomechanical thrombolysis has been reported,
however the true incidence is unknown.
Case reports: An 18-year-old male athlete with Paget von Schroetter
disease underwent PMT using the AngioJet device and thrombolysis with
tissue plasminogen activator. Total PMT volume was 200 mL. Postopera-
tively, the patient developed hematuria, and elevated serum creatinine.
Urine output was normal, and his creatinine slowly normalized without
intervention. He successfully underwent first rib resection. A 42 year-old
male with factor V Leiden and protein C and S deficiency, but normal
preoperative serum creatinine, developed recurrent bilateral ileofemoral
deep venous thromboses. He underwent “power pulse thrombolysis” using
the AngioJet device, and subsequent catheter directed thrombolysis. Total
PMT volume was 300 mL with additional infusion of tissue plasminogen
activator. Intraoperative hematuria was noted, and postoperatively, the
patient developed an acute increase in serum creatinine. Urine output was
normal, and investigations regarding the etiology of the acute kidney injury
were inconclusive. There were no laboratory signs of hemolysis, interstitial
nephritis, or hemodynamically mediated kidney injury.
Conclusions: These two cases illustrate acute kidney injury after PMT
and thrombolysis for venous thrombosis. PMT can lead to hemolysis in cases
of high-volume injection and aspiration. In both patients, hematuria was
present during or immediately after pharmacomechanical thrombolysis.
Limiting PMT volume appears to ameliorate the risk of hemolysis, but in the
patients presented, PMT using the AngioJet device was performed with
500 mL. As the use of endovascular techniques for thrombosis increases,
further studies are needed to assess the relationship of PMT, postoperative
hemolysis, and its impact on renal function. Vigilance of PMT volume and
renal status in these patients appears warranted.
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Long-term mechanical circulatory support devices are currently an
established therapy for the management of end-stage heart failure and
current evidence supports their superiority compared with maximal medical
therapy in these patients. Implantation of left ventricular assist devices
(LVAD) as destination therapy in patients considered ineligible for heart
transplantation has resulted in improved survival, quality of life, and func-
tional status. Screening for peripheral arterial disease and abdominal aortic
aneurysm (AAA) before LVAD implantation is recommended. Although
repair of AAA before during LVAD placement has been reported, surveil-
lance and management strategies of AAA after LVAD implantation need to
be further investigated.We describe our surveillance program,management,
and operative strategies in two patients on destination LVAD therapy who
underwent successful endovascular AAA repair. Meticulous preoperative
workup and counseling, with special attention to bridging of anticoagula-
tion therapies and careful intraoperative monitoring, including the hemo-
dynamic management of a nonpulsatile, continuous-flow system are critical
to successful outcomes. Endovascular AAA repair is feasible in patients with
destination LVAD therapy and should be considered in those with AAA and
a reasonable life expectancy.
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Objectives: This report describes the diagnosis and treatment of a
complex thoracic aneurysm in a patient with relapsing polychondritis (RP).
Methods:Review of this rare disorder, its complications, and principles
of thoracic aneurysm repair.
Results: A 29 year-old woman with a history of RP and open repair of
a proximal descending thoracic aneurysm presented with hemoptysis and
right lower lobe blastomycosis pneumonia. Chest computed tomography
showed two areas of thoracic aneurysmal dilatation—at the ascending aorta/
arch and the distal descending aorta, straddling the area of her previous open
repair (Fig 1). The patient was initially treated conservatively, but returned 3
months later with symptomatic aneurysm expansion of the ascending/arch
aneurysm. She therefore underwent ascending and aortic arch replacement
with reimplantation of the arch vessels (Fig 2). She subsequently underwent
endovascular repair of the distal descending thoracic aorta when the distal
aneurysm expanded and became symptomatic (Figs 3 and 4). RP is a rare
disease with an incidence of 3.5 per million individuals annually, 1% of
whomdevelop aneurysmal disease. Antibodies to type II collagen are present
in 50% to 60% of these, and there is an association with HLA-DR4. Areas
most commonly affected include the auricular cartilage and the tracheo-
bronchial tree. Medical management is aimed at immunosuppression via
steroids and monoclonal antibodies (ie infliximab). First described in 1923
by Jaksch-Wartenhorst, thoracic aneurysm repair in these patients has been
most recently described in 2006 by Caceres. To our knowledge this is the
youngest reported patient with RP to require thoracic aneurysm repair; the
only description of repair of both the ascending and descending aorta in a
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